Renal Function Tests Market – Introduction
Kidneys are among the most vital organs of the human body. Kidneys act as blood filters, reabsorbing the essential elements and removing the water-soluble waste products from the blood. Since kidneys play such an important role, these require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth.
Functional damage of kidneys is common across the world, and its incidence is increasing globally. High blood pressure, hypertension, diabetes, excessive alcohol consumption, frequent urges to urinate, blood in urine, difficulty in urination, and puffiness in the hands and feet due to buildup of fluids in the body are the major symptoms and causative factors of chronic kidney disease.
Obtain Report Details @ https://www.transparencymarketresearch.com/renal-function-tests-market.html
Renal function tests measure the amount of certain substances released into the blood or urine by the kidneys. The kidney function tests are performed to identify the renal disease to determine appropriate patient management and prevent further deterioration of renal function.
Renal Function Tests Market – Competitive Landscape
- In October 2018, Siemens Healthineers AG entered an original equipment manufacturer (OEM) alliance with Israel-based Healthy.io Company. The alliance aimed at integration of urinalyses reagents of former company into smartphone-based urinalysis system of Healthy.io. To provide patients with increased access to home based urinalysis testing for detection of chronic kidney disease.
- Siemens Healthineers formed a strategic alliance with the National Kidney Foundation and to offer no-cost urine testing to patients with high risk of kidney disease in the U.S. This is anticipated to improve the diagnosis and treatment of kidney disease and strengthen its geographic presence.
Siemens Healthineers AG
Founded in 1847, Siemens Healthineers AG is a global provider of health care solutions and services. The company develops, manufactures, and sells a diverse range of market-leading and innovative diagnostic, imaging, and advanced therapy products and services to healthcare providers around the world. The company focuses on investment in R&D to develop products for the effective treatment of renal disorders as well as engage in strategic collaborations to create awareness and foster adoption of kidney function tests.
- Hoffmann-La Roche
Incorporated in 1896, F. Hoffmann-La Roche is based in Basel, Switzerland. F. Hoffmann-La Roche Ltd. is a prominent biotechnology company that develops and markets breakthrough medicines and diagnostic solutions across various medical specialties. The company operates through two major divisions: pharmaceutical and diagnostics. The company offers diverse products and solutions in the fields of clinical chemistry & immunoassay, molecular diagnostics, tissue diagnostics, point-of-care diagnostics, and hematology and hemostasis. It provides various test kits such as Chemstrip test or Combur-Test for the detection of albumin in urine for early diagnosis of chronic kidney disease.
Other prominent players operating in the global renal function tests market are Sysmex Corporation, OPTI Medical, Beckman Coulter, ARKRAY, Nova Biomedical, 77 Elektronika, Abbott, Metabolic Solutions Development Company, LLC, IDEXX Laboratories, URIT Medical, Randox Laboratories, and Otsuka Holdings Co., Ltd., among others.
Identify the key factors that will drive your company’s growth, Request a brochure of this report here
Renal Function Tests Market – Dynamics
Rise in Incidence of Chronic Kidney Disease Globally Drives Market
Increase in incidence of chronic kidney diseases (CKD) across the globe is a major factor driving the global renal function tests market. For instance, 1 in 4 men and 1 in 5 women aged 65 years and above suffer from chronic kidney disease across the globe. Currently, 10% to 15% of the global population is affected with chronic kidney disease. According to the World Health Organization, each year, more than 1.4 million people across the world undergo kidney replacement therapy, with the incidence rate of chronic kidney disease increasing by nearly 8% annually. Moreover, according to Kidney Care UK, currently, 3 million people are affected by chronic kidney disease in the U.K. All these factors are anticipated to boost the demand for renal function tests in the near future.